PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Completed · Phase 2

Conditions studied: Carcinoma, Non Small Cell Lung

In brief

To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.

Key facts

Study ID

NCT00548093

Run by

Pfizer

People needed

66

Starts

2008-04-29

Expected to finish

2012-06-11

Last updated by the study team

2019-05-21

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced Non-Small Cell Lung Cancer (NSCLC)
• Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib.
• Prior treatment with no more than two chemotherapy regimens, including adjuvant or combined modality treatment.
• Measurable disease .
• Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
• Tissue available for KRAS/ EGFR testing
• Creatinine clearance > 40 cc/min or serum creat < 1.5 x ULN

You may not qualify if…

• Chemotherapy
• Radiotherapy
• Biological or investigational agents within 4 weeks of baseline disease assessment.
• Patients who lack of tolerance of erlotinib therapy.

Where it is running

• City of Hope — Duarte, California, United States
• City of Hope Medical Group — Pasadena, California, United States
• City of Hope South Pasadena Cancer Center — South Pasadena, California, United States
• Rocky Mountain Lions Eye Institute — Aurora, Colorado, United States
• University of Colorado Hospital, Anschutz Cancer Pavilion — Aurora, Colorado, United States
• University of Colorado Hospital, Anschutz Inpatient Pavilion — Aurora, Colorado, United States
• University of Colorado Hospital — Aurora, Colorado, United States
• Grady Health Systems — Atlanta, Georgia, United States
• Emery University Hospital Midtown — Atlanta, Georgia, United States
• Emory Clinic — Atlanta, Georgia, United States
• Emory University Hospital — Atlanta, Georgia, United States
• Winship Cancer Institute — Atlanta, Georgia, United States
• CCR, National Cancer Institute — Bethesda, Maryland, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Karmanos Cancer Institute/Wayne State University — Detroit, Michigan, United States
• Lawrence and Idell Weisberg Cancer Treatment Center — Farmington Hills, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.